Veliparib
Based on 51 publication(s) in Google Scholar
Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with Kis of 5.2 and 2.9 nM, respectively.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.77%
- No. CAS: 912444-00-9
- Fòrmula: C13H16N4O
- Peso molecular:244.29
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Veliparib
More- Nature. 2025 Sep;645(8082):1071-1080. [Abstract]
- Cancer Discov. 2017 Sep;7(9):984-998. [Abstract]
- Cancer Res. 2025 May 14. [Abstract]
- Nat Commun. 2026 Feb 12;17(1):1214. [Abstract]
- Nat Commun. 2021 Jun 24;12(1):3931. [Abstract]
- Mol Cell. 2026 Apr 16;86(8):1427-1440.e5. [Abstract]
- Nat Chem Biol. 2025 Jun 27. [Abstract]
- Theranostics. 2020 Jul 25;10(21):9477-9494. [Abstract]
- Adv Sci (Weinh). 2025 Aug;12(32):e02448. [Abstract]
- Adv Sci (Weinh). 2025 Jul 16:e15585. [Abstract]
- Cell Death Dis. 2024 Dec 18;15(12):914. [Abstract]
- Cancer Genet. 2019 Nov:239:26-32. [Abstract]
- Clin Cancer Res. 2017 Feb 15;23(4):1001-1011. [Abstract]
- Acta Pharmacol Sin. 2022 Apr;43(4):781-787. [Abstract]
- J Transl Med. 2024 Nov 26;22(1):1062. [Abstract]
- Oncogene. 2022 Sep;41(37):4271-4281. [Abstract]
- Int J Biol Macromol. 2023 Jul 1;242(Pt 2):124794. [Abstract]
- Sci Signal. 2025 Oct 21;18(909):eadx2532. [Abstract]
- J Invest Dermatol. 2024 Dec;144(12):2695-2705.e8. [Abstract]
- Mol Cancer Ther. 2019 Nov;18(11):2063-2073. [Abstract]
- Ecotoxicol Environ Saf. 2023 Mar 1:252:114630. [Abstract]
- Cells. 2021 Mar 9;10(3):599. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Neoplasia. 2025 May:63:101152. [Abstract]
- Cancers (Basel). 2024 Nov 5;16(22):3728. [Abstract]
- Cancers (Basel). 2024 Oct 10;16(20):3441. [Abstract]
- Nanomaterials. 2021 Jun 8;11(6):1514. [Abstract]
- Neoplasia. 2019 Jun;21(6):533-544. [Abstract]
- Neoplasia. 2018 May;20(5):478-488. [Abstract]
- Cell Signal. 2025 Jul:131:111709. [Abstract]
- Front Mol Biosci. 2021 Apr 29:8:633344. [Abstract]
- BMC Cancer. 2022 Mar 23;22(1):312. [Abstract]
- Analyst. 2025 Dec 1;150(24):5501-5513. [Abstract]
- Front Oncol. 2021 Jul 9:11:681441. [Abstract]
- Biomed Res Int. 2023 Feb 6:2023:7891753. [Abstract]
- FEBS Open Bio. 2025 Dec 5. [Abstract]
- EJNMMI Res. 2025 Apr 29;15(1):50. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Oct 1:1154:122195. [Abstract]
- Oncol Lett. 2025 Jan 7;29(3):128. [Abstract]
- J Vet Med Sci. 2018 Nov 23;80(11):1775-1781. [Abstract]
- EANM Innovation. 2026 May 19;3:100274.
- bioRxiv. 2025 Nov 4:2025.11.03.686423. [Abstract]
- Research Square Preprint. 2024 Nov 06.
- Res Sq. 2024 Feb 21:rs.3.rs-3970470. [Abstract]
- Research Square Preprint. 2021 Feb.
- Patent. US20200129476A1
- Patent. US20200078369A1
- Patent. US20180362972A1.
- Patent. US20180263995A1.
- Int J Curr Res Acad Rev. 2017; 5(3): 53-64.
- Electrostatics Joint Conference. 2016 July.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
WB
-
RT-PCR
-
Bio/Physico-chemical Assay
-
WB
Actividad biológica
|
PARP-2 2.9 nM (Ki) |
PARP-1 5.2 nM (Ki) |
Autophagy |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
133.5 μM
Compound: ABT-888
|
Inhibition of PARP1 in human A549 cells assessed as potentiation of TMZ-mediated cytotoxicity by measuring TMZ IC50 for growth inhibition at 0.5 uM by SRB assay (Rvb TMZ IC50 = 295 uM)
Inhibition of PARP1 in human A549 cells assessed as potentiation of TMZ-mediated cytotoxicity by measuring TMZ IC50 for growth inhibition at 0.5 uM by SRB assay (Rvb TMZ IC50 = 295 uM)
|
[PMID: 27353531] |
| A549 | IC50 |
15.22 μM
Compound: ABT-888
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38554475] |
| A549 | IC50 |
>10 μM
Compound: VI
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 38776806] |
| CAPAN-1 | IC50 |
39.7 μM
Compound: ABT-888
|
Antiproliferative activity against BRCA2 gene mutated human Capan1 cells after 72 hrs by SRB assay
Antiproliferative activity against BRCA2 gene mutated human Capan1 cells after 72 hrs by SRB assay
|
[PMID: 24398383] |
| CAPAN-1 | EC50 |
>10000 nM
Compound: 1; ABT-888
|
Cytotoxicity against BRCA2-deficient human Capan1 cells
Cytotoxicity against BRCA2-deficient human Capan1 cells
|
[PMID: 26652717] |
| DLD-1 | IC50 |
0.75 μM
Compound: 5
|
Antiproliferative activity against human DLD-1 deficient in BRCA-2 cells measured after 7 days
Antiproliferative activity against human DLD-1 deficient in BRCA-2 cells measured after 7 days
|
[PMID: 34570508] |
| DLD-1 | IC50 |
69 μM
Compound: Veliparib
|
Cytotoxicity against human DLD-1 cells expressing BRCA2 assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis
Cytotoxicity against human DLD-1 cells expressing BRCA2 assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis
|
[PMID: 37484567] |
| DLD-1 | IC50 |
8.85 μM
Compound: Veliparib
|
Cytotoxicity against human DLD-1 cells with BRCA2 knockout assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis
Cytotoxicity against human DLD-1 cells with BRCA2 knockout assessed as reduction in cell proliferation incubated for 5 days by sulforhodamine B analysis
|
[PMID: 37484567] |
| FaDu | IC50 |
>10 μM
Compound: VI
|
Antiproliferative activity against human FaDu cells assessed as inhibition of cell growth by MTT assay
Antiproliferative activity against human FaDu cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 38776806] |
| HCC1937 | IC50 |
97.16 μM
Compound: ABT-888
|
Antiproliferative activity against BRCA1 gene mutated human HCC1937 cells after 72 hrs by SRB assay
Antiproliferative activity against BRCA1 gene mutated human HCC1937 cells after 72 hrs by SRB assay
|
[PMID: 24398383] |
| HCT-116 | IC50 |
64 μM
Compound: ABT-888
|
Cytotoxicity against human HCT116 cells by SRB assay
Cytotoxicity against human HCT116 cells by SRB assay
|
[PMID: 27353531] |
| HeLa | IC50 |
18.11 μM
Compound: ABT-888
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38554475] |
| HepG2 | IC50 |
13.69 μM
Compound: ABT-888
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38554475] |
| HGC-27 | IC50 |
16.03 μM
Compound: ABT-888
|
Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HGC-27 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38554475] |
| HH | IC50 |
>10 μM
Compound: VI
|
Antiproliferative activity against human HH cells assessed as inhibition of cell growth by MTT assay
Antiproliferative activity against human HH cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 38776806] |
| HL-60 | IC50 |
>10 μM
Compound: VI
|
Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth by MTT assay
Antiproliferative activity against human HL-60 cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 38776806] |
| HUVEC | IC50 |
>100 μM
Compound: Veliparib
|
Inhibition of cell proliferation in HUVECs
Inhibition of cell proliferation in HUVECs
|
[PMID: 38678823] |
| Jurkat | EC50 |
160 μM
Compound: ABT-888
|
Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay
Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay
|
[PMID: 23850199] |
| Jurkat | EC50 |
3 μM
Compound: ABT-888
|
Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay in presence of 100 uM of temozolomide
Inhibition of PARP1 in human Jurkat cells assessed as reduction of cell viability after 96 hrs by MTS assay in presence of 100 uM of temozolomide
|
[PMID: 23850199] |
| K562 | IC50 |
>10 μM
Compound: VI
|
Antiproliferative activity against human K562 cells assessed as inhibition of cell growth by MTT assay
Antiproliferative activity against human K562 cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 38776806] |
| LoVo | EC50 |
5.94 nM
Compound: 1; ABT-888
|
Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay
Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay
|
[PMID: 26652717] |
| LoVo | GI50 |
6203 nM
Compound: 1; ABT-888
|
Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay
Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay
|
[PMID: 26652717] |
| MCF7 | IC50 |
>100 μM
Compound: Veliparib
|
Inhibition of cell proliferation in human MCF7 cells
Inhibition of cell proliferation in human MCF7 cells
|
[PMID: 38678823] |
| MDA-MB-231 | IC50 |
>10 μM
Compound: VI
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 38776806] |
| MDA-MB-436 | IC50 |
>100 μM
Compound: Veliparib
|
Inhibition of cell proliferation in human MDA-MB-436 cells assessed as PARP trapping effect
Inhibition of cell proliferation in human MDA-MB-436 cells assessed as PARP trapping effect
|
[PMID: 38678823] |
| MDA-MB-468 | EC50 |
43 μM
Compound: Veliparib
|
Growth inhibition of human MDA-MB-468 cells after 72 hrs by SRB assay
Growth inhibition of human MDA-MB-468 cells after 72 hrs by SRB assay
|
[PMID: 27561983] |
| MOLT-4 | IC50 |
>10 μM
Compound: VI
|
Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth by MTT assay
Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 38776806] |
| MRC5 | EC50 |
>10 μM
Compound: 1; ABT-888
|
Cytotoxicity against human MRC5 cells
Cytotoxicity against human MRC5 cells
|
[PMID: 26652717] |
| PC-3 | IC50 |
>10 μM
Compound: VI
|
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth by MTT assay
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 38776806] |
| Sf9 | IC50 |
<10 nM
Compound: Vel
|
Inhibition of human N-terminal GST-tagged PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay
Inhibition of human N-terminal GST-tagged PARP2 (2 to 583 residues) expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay
|
[PMID: 31042381] |
| Sf9 | IC50 |
1.5 nM
Compound: Vel
|
Inhibition of human full-length N-terminal GST-tagged PARP1 expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay
Inhibition of human full-length N-terminal GST-tagged PARP1 expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay
|
[PMID: 31042381] |
| SiHa | IC50 |
>10 μM
Compound: VI
|
Antiproliferative activity against human SiHa cells assessed as inhibition of cell growth by MTT assay
Antiproliferative activity against human SiHa cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 38776806] |
| SW-620 | EC50 |
27.1 μM
Compound: Veliparib
|
Growth inhibition of human SW620 cells after 72 hrs by SRB assay
Growth inhibition of human SW620 cells after 72 hrs by SRB assay
|
[PMID: 27561983] |
Veliparib (ABT-888) is also tested against SIRT2, an enzyme that also uses NAD+ for catalysis, and found to be inactive (>5,000 nM). The receptor profile of Veliparib is determined in a panel of 74 receptor-binding assays at a concentration of 10 μM. Veliparib displaces control-specific binding at 50% or greater at the human H1(61%), the human 5-HT1A (91%), and the human 5-HT7 (84%) sites only. The IC50s for these three receptors are 5.3, 1.5, and 1.2 μM, respectively[1].
c-Met knockdown cells show 4.2- (shMet-A; 95% CI=4-4.5) or 4.6-fold (shMet-B; 95% CI=4.4-4.8) growth inhibition when treated with 60 μM Veliparib (ABT-888). When treated with 38 μM Veliparib, c-Met knockdown cells show 2- (shMet-A; 95% CI=1.5-2.5) or 1.9-fold (shMet-B; 95% CI=1.3-2.5) growth inhibition[2].
In HaCaT cells, at 6 h post-treatment by Veliparib (ABT-888), cell viability is significantly increases under 1,000 μM sulfur mustard (SM) exposure, whereas Veliparib does not protect cell viability under 100 μM SM exposure. Moreover, the addition of Veliparib no longer shows the protective effect at 24 h post SM exposure[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 912444-00-9
-
Appearance Solid
-
Peso molecular 244.29
-
Fòrmula C13H16N4O
-
Color White to off-white
-
SMILES
O=C(C1=C2NC([C@@]3(NCCC3)C)=NC2=CC=C1)N
-
Synonyms
ABT-888
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (51)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 Sep;645(8082):1071-1080. PMID: 40804522 -
Cancer Discov
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. [Abstract]2017 Sep;7(9):984-998. PMID: 28588062 -
Cancer Res
SMARCA4 loss increases RNA Polymerase II pausing and elevates R-loops to inhibit BRCA1-mediated repair in ovarian cancer. [Abstract]2025 May 14. PMID: 40366633 -
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175 -
Nat Commun
2021 Jun 24;12(1):3931. PMID: 34168143
Veliparib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 24;12(1):3931. [Abstract]
Veliparib (10 μM; 24 h). Immunoblots for STAT1a S727p in iBMDMs treated with IFNγ ± Veliparib (Vel.) as indicated.
Veliparib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 24;12(1):3931. [Abstract]
Veliparib (10 μM; 24 h). Bar graphs showing the relative mRNA levels upon treatment IFNγ treatment ± Veliparib (Vel.).
Veliparib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 24;12(1):3931. [Abstract]
Veliparib (10 μM; 24 h). PARP catalytic inhibition results in attenuation of NOS activity in iBMDMs. The cells were treated with IFNγ and Veliparib for 24 hours as indicated.
-
Mol Cell
2026 Apr 16;86(8):1427-1440.e5. PMID: 41935526 -
Nat Chem Biol
2025 Jun 27. PMID: 40579572 -
Theranostics
Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas. [Abstract]2020 Jul 25;10(21):9477-9494. PMID: 32863940 -
Adv Sci (Weinh)
Combining PIM-2 and PARP1 Inhibitors Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells through NKG2D Binding. [Abstract]2025 Aug;12(32):e02448. PMID: 40557764 -
Adv Sci (Weinh)
Disruption of ARID1B Recruitment to the Nuclear Pore Complex as a New Anticancer Therapeutic Strategy. [Abstract]2025 Jul 16:e15585. PMID: 40671262
Veliparib purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 16:e15585. [Abstract]
Veliparib (0-100 μM; 72 h). Dose‐response curves for Veliparib after 72 h of treatment in MDA‐MB‐468 cells comparing empty vector control (Control) and ARID1B OE cells.
-
Cell Death Dis
Mitochondria-targeted oligomeric α-synuclein induces TOM40 degradation and mitochondrial dysfunction in Parkinson's disease and parkinsonism-dementia of Guam. [Abstract]2024 Dec 18;15(12):914. PMID: 39695091 -
Cancer Genet
A novel BRCA1 germline mutation promotes triple-negative breast cancer cells progression and enhances sensitivity to DNA damage agents. [Abstract]2019 Nov:239:26-32. PMID: 31476665 -
Clin Cancer Res
Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors. [Abstract]2017 Feb 15;23(4):1001-1011. PMID: 27559053 -
Acta Pharmacol Sin
2022 Apr;43(4):781-787. PMID: 34294887 -
J Transl Med
Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions. [Abstract]2024 Nov 26;22(1):1062. PMID: 39587643 -
Oncogene
A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer. [Abstract]2022 Sep;41(37):4271-4281. PMID: 35933519 -
Int J Biol Macromol
Exploring the stabilizing effect on the i-motif of neighboring structural motifs and drugs. [Abstract]2023 Jul 1;242(Pt 2):124794. PMID: 37182626 -
Sci Signal
PARP1-mediated PARylation of TEAD4 stabilizes the YAP1-TEAD4 complex and promotes growth and immune evasion in breast cancer cells. [Abstract]2025 Oct 21;18(909):eadx2532. PMID: 41118450 -
J Invest Dermatol
TRPV3-Activated PARP1/AIFM1/MIF Axis through Oxidative Stress Contributes to Atopic Dermatitis. [Abstract]2024 Dec;144(12):2695-2705.e8. PMID: 38823435 -
Mol Cancer Ther
PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation. [Abstract]2019 Nov;18(11):2063-2073. PMID: 31413177 -
Ecotoxicol Environ Saf
PARP1 promotes NLRP3 activation via blocking TFEB-mediated autophagy in rotenone-induced neurodegeneration. [Abstract]2023 Mar 1:252:114630. PMID: 36764072 -
Cells
New Insights into the Significance of PARP-1 Activation: Flow Cytometric Detection of Poly(ADP-Ribose) as a Marker of Bovine Intramammary Infection. [Abstract]2021 Mar 9;10(3):599. PMID: 33803196 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Neoplasia
Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma. [Abstract]2025 May:63:101152. PMID: 40096771 -
Cancers (Basel)
2024 Nov 5;16(22):3728. PMID: 39594684 -
Cancers (Basel)
Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP Inhibitors. [Abstract]2024 Oct 10;16(20):3441. PMID: 39456536 -
Nanomaterials
Co-Encapsulation of Methylene Blue and PARP-Inhibitor into Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Enhanced PDT of Cancer. [Abstract]2021 Jun 8;11(6):1514. PMID: 34201069 -
Neoplasia
DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors. [Abstract]2019 Jun;21(6):533-544. PMID: 31029033 -
Neoplasia
Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. [Abstract]2018 May;20(5):478-488. PMID: 29605721 -
Cell Signal
2025 Jul:131:111709. PMID: 40037423 -
Front Mol Biosci
Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma. [Abstract]2021 Apr 29:8:633344. PMID: 33996894 -
BMC Cancer
PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth. [Abstract]2022 Mar 23;22(1):312. PMID: 35321693 -
Analyst
Determination of veliparib metabolic stability in the human liver microsomes using a hydrophilic interaction UPLC-MS/MS quantitative method: greenness assessment with an in silico study for ADME, DEREK alarms and metabolic lability. [Abstract]2025 Dec 1;150(24):5501-5513. PMID: 41231074 -
Front Oncol
The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma. [Abstract]2021 Jul 9:11:681441. PMID: 34307148 -
Biomed Res Int
ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines. [Abstract]2023 Feb 6:2023:7891753. PMID: 36794257 -
FEBS Open Bio
Anticancer sensitivities and biological characteristics of HCT116 cells resistant to the selective poly(ADP-ribose) glycohydrolase inhibitor. [Abstract]2025 Dec 5. PMID: 41347713 -
EJNMMI Res
Evaluation of a simplified radiolabeling method for a PARP inhibitor in an animal model of breast cancer. [Abstract]2025 Apr 29;15(1):50. PMID: 40301197 -
J Chromatogr B Analyt Technol Biomed Life Sci
Development and validation of an HPLC-MS/MS method for the determination of filgotinib, a selective Janus kinase 1 inhibitor: Application to a metabolic stability study. [Abstract]2020 Oct 1:1154:122195. PMID: 32943176 -
Oncol Lett
DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines. [Abstract]2025 Jan 7;29(3):128. PMID: 39822940 -
J Vet Med Sci
2018 Nov 23;80(11):1775-1781. PMID: 30249935
Veliparib purchased from MedChemExpress. Usage Cited in: J Vet Med Sci. 2018 Nov 23;80(11):1775-1781. [Abstract]
PK-15 cells are incubated with 20 μM ABT-888 for 1 hr and subsequently infected with transmissible gastroenteritis virus (TGEV) for 36 hr. Cells are collected and then subjected to Western blot analysis for PARP-1.
-
-
bioRxiv
Design and Development of DNA Damage Chemical Inducers of Proximity (DD-CIP) for Targeted Cancer Therapy. [Abstract]2025 Nov 4:2025.11.03.686423. PMID: 41278667 -
-
Res Sq
Mitochondria-Targeted Oligomeric α-Synuclein Induces TOM40 Degradation and Mitochondrial Dysfunction in Parkinson's Disease and Parkinsonism-Dementia of Guam. [Abstract]2024 Feb 21:rs.3.rs-3970470. PMID: 38464024 -
-
-
-
-
-
-
Solvente y solubilidad
DMSO : ≥ 29 mg/mL (118.71 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (8.51 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (8.51 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
PARP1 enzyme activity is measured by using a commercial assay kit with the exception that cell lysates containing wild-type PARP1 or PARP Y907 mutant are used in place of the PARP1 protein included with the kit. Total lysate (500 ng) is added to each reaction. The dose course of PARP inhibitor Veliparib (ABT-888) is from 0.01 to 1,000 μM. PARP enzyme activity of wild-type and mutants is determined after incubation with the substrate is measured using a plate reader[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cell viability is quantified using the Cell Counting Kit-8 (CCK-8). This assay is based on Dojindo’s highly water-soluble tetrazolium salt. WST-8 is reduced by dehydrogenases in cells to give an orange, water-soluble formazan dye. The amount of the formazan dye generated by dehydrogenases in cells is directly proportional to the number of living cells. Briefly, exponentially growing HaCaT cells are seeded in 96-well plates at a density of 10,000 cells/well. 6 h or 24 h after exposure to sulfur mustard (SM) and the administration of Veliparib, the CCK-8 reagent is added[3.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[2]
MDA-MB-231 (0.5×106), HCC1937 (2×106) or MCF-7 (5×106) cells are injected into the mammary fat pads of female nude (Swiss Nu/Nu) mice of 6-8 weeks of age. A1034 (0.5×106) cells are injected into the mammary fat pads of female FVB/NJ mice of 6-8 weeks of age. H1993 (0.5×106) cells are injected subcutaneously into the right flank of female nude (Swiss Nu/Nu) mice of 6-8 weeks of age. When the tumor volume reaches 50 mm3, PF-02341066 (5 mg/kg) and Foretinib (5 mg/kg), AG014699 (5 mg/kg) and Veliparib (25 mg/kg), dissolved in aqueous 50 mM sodium acetate, pH 4, are administered to mice five times per week as single agents or in combination for the number of days specified in the figure legend. Tumor is measured at the indicated time points, and tumor volume is calculated by the formula: π/6×length×width2. For MDA-MB-231 and A1034 xenograft mouse models, mice are imaged before and after treatment using the IVIS Imaging System to assess tumor growth. Mice are injected with 100 μL of D-luciferin (15 mg/mL in PBS).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Donawho CK, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007 May 1;13(9):2728-37. [Content Brief]
[2]. Du Y, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016 Feb;22(2):194-201. [Content Brief]
[3]. Liu F, et al. Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo. PeerJ. 2016 Apr 4;4:e1890. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.0935 mL | 20.4675 mL | 40.9350 mL | 102.3374 mL |
| 5 mM | 0.8187 mL | 4.0935 mL | 8.1870 mL | 20.4675 mL | |
| 10 mM | 0.4093 mL | 2.0467 mL | 4.0935 mL | 10.2337 mL | |
| 15 mM | 0.2729 mL | 1.3645 mL | 2.7290 mL | 6.8225 mL | |
| 20 mM | 0.2047 mL | 1.0234 mL | 2.0467 mL | 5.1169 mL | |
| 25 mM | 0.1637 mL | 0.8187 mL | 1.6374 mL | 4.0935 mL | |
| 30 mM | 0.1364 mL | 0.6822 mL | 1.3645 mL | 3.4112 mL | |
| 40 mM | 0.1023 mL | 0.5117 mL | 1.0234 mL | 2.5584 mL | |
| 50 mM | 0.0819 mL | 0.4093 mL | 0.8187 mL | 2.0467 mL | |
| 60 mM | 0.0682 mL | 0.3411 mL | 0.6822 mL | 1.7056 mL | |
| 80 mM | 0.0512 mL | 0.2558 mL | 0.5117 mL | 1.2792 mL | |
| 100 mM | 0.0409 mL | 0.2047 mL | 0.4093 mL | 1.0234 mL |
Veliparib Related Classifications
HY-10129 Related Classifications
Powered by Bioz